Twist Bioscience Co. (NASDAQ:TWST) Shares Bought by BNP Paribas Financial Markets

BNP Paribas Financial Markets raised its stake in Twist Bioscience Co. (NASDAQ:TWST) by 138.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90,527 shares of the company’s stock after acquiring an additional 52,495 shares during the period. BNP Paribas Financial Markets owned 0.15% of Twist Bioscience worth $4,207,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the stock. Van ECK Associates Corp raised its holdings in shares of Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after buying an additional 267 shares during the last quarter. US Bancorp DE raised its holdings in shares of Twist Bioscience by 72.0% in the fourth quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after buying an additional 601 shares during the last quarter. KBC Group NV raised its holdings in shares of Twist Bioscience by 71.4% in the fourth quarter. KBC Group NV now owns 2,942 shares of the company’s stock valued at $137,000 after buying an additional 1,226 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Twist Bioscience by 19.9% in the fourth quarter. Blue Trust Inc. now owns 4,567 shares of the company’s stock valued at $206,000 after buying an additional 757 shares during the last quarter. Finally, Wealthfront Advisers LLC purchased a new stake in shares of Twist Bioscience in the fourth quarter valued at about $209,000.

Insiders Place Their Bets

In other Twist Bioscience news, SVP Paula Green sold 918 shares of the business’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total value of $37,555.38. Following the transaction, the senior vice president now owns 130,912 shares in the company, valued at $5,355,609.92. The trade was a 0.70% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Emily M. Leproust sold 2,402 shares of the business’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $98,265.82. Following the completion of the transaction, the chief executive officer now owns 662,692 shares in the company, valued at $27,110,729.72. This represents a 0.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,991 shares of company stock worth $742,654 in the last quarter. 3.01% of the stock is owned by corporate insiders.

Twist Bioscience Stock Performance

NASDAQ:TWST opened at $29.52 on Thursday. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $1.77 billion, a price-to-earnings ratio of -8.73 and a beta of 2.54. The firm’s fifty day simple moving average is $38.11 and its 200 day simple moving average is $43.46. Twist Bioscience Co. has a twelve month low of $29.45 and a twelve month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The business had revenue of $92.79 million for the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. As a group, equities research analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on TWST. Scotiabank reaffirmed an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Barclays cut their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. Robert W. Baird cut their price target on shares of Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating for the company in a report on Tuesday, May 6th. JPMorgan Chase & Co. cut their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating for the company in a report on Tuesday, May 6th. Finally, Guggenheim reissued a “buy” rating and set a $50.00 price target on shares of Twist Bioscience in a report on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.40.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.